中文摘要：

目的系统评价新一代药物洗脱支架植入术后双联抗血小板治疗不同疗程的有效性和安全性。方法计算机检索MEDLINE、The Cochrane Library（2015年2期）、EMbase、CBM、CNKI、Wan Fang Data数据库，搜集新一代药物洗脱支架植入术后双联抗血小板治疗周期的相关研究，检索时限均从建库至2015年4月。由两名评价员独立筛选文献、提取资料并评价纳入研究的偏倚风险后，采用RevMan5．3软件进行Meta分析。结果共纳入6个研究。Meta分析结果显示：与12个月抗血小板治疗组相比，6个月抗血小板治疗组的出血事件发生率较低[OR=0．48，95％CI（0．26，0．89），P=0．02]，其他方面两组差异无统计学意义。与24个月抗血小板治疗组相比，12个月抗血小板治疗组的支架内血栓发生率较高[OR=2．50，95％CI（1．13，5．61），P=0．02]，而出血事件发生率较低[OR=0．25，95％CI（0．07，0．89），P=0．03]，其他方面两组差异无统计学意义。结论植入新一代药物洗脱支架后，患者服用6个月双联抗血小板治疗相对安全有效，而12个月和24个月双联抗血小板治疗会明显增加出血发生率。受纳入研究的数量和质量的限制，上述结论尚需开展更多高质量研究予以验证。

英文摘要：

Objective To systematically review the efficacy and safety of different duration of dual antiplatelet therapies in patients undergoing new-generation drug-eluting stents implantation. Methods Such databases as MEDLINE, The Cochrane Library （Issue 2, 2015）, EMbase, CBM, CNKI and WanFang Data were searched to collect studies on the different duration of dual antiplatelet therapies in patients undergoing new-generation drug-eluting stents implantation from inception to April 2015. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, meta-analysis was performed using RevMan 5.3 software. Results Six trials were included. The results of meta-analysis showed： compared with 12 months dual antiplatelet therapy group, the incidence of bleeding in the 6 months dual antiplatelet therapy group was lower （OR=0.48, 95%CI 0.26 to 0.89, P=0.02）. There were no significant differences in incidence of myocardial infarction, all cause mortality, stroke and stent thrombosis between two groups. Compared with 24 months dual antiplatelet therapy group, the incidence of stent thrombosis in the 12 months dual antiplatelet therapy group was higher （OR=2.50, 95%CI 1.13 to 5.61, P=0.02）, but the incidence of bleeding in 12 months dual antiplatelet therapy group was lower （OR=0.25, 95%CI 0.07 to 0.89, P=0.03）. No significant differences were found in the incidence of myocardial infarction, all cause mortality and stroke between 12 months dual antiplatelet therapy group and 24 months dual antiplatelet therapy group. Conclusions 6 months dual antiplatelet therapy following new-generation drug-eluting stent implantation is relatively more safe and efficacy. Thereis significant increase of incidence of bleeding in 12 or 24 months dual antiplatelet therapy. Due to the limited quantity and quality of included studies, the above results are needed to be validated by more high quality studies.